← Leaderboards
Eric Sebastian Fischer
Stanford University
$7,372,602
Attributed
$9,331,350
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,331,350 · 3
By mechanism
R01$9,331,350 · 3
Top collaborators
- Nathanael Schiander Gray8 shared
Others in their field
Other Emerging Leaders on “Novel Therapeutics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Research focus
Novel TherapeuticsUbiquitin-Protein LigasePharmaceutical PreparationsProteomicsLigaseProtein DegradationComplexProteinsRecruitStructureRbx1 GeneUbiquitinationMalignant NeoplasmsInterestSmall MoleculeResponseCancer TherapyMass Spectrum AnalysisIn VivoExhibitsBindingCellsThalidomideDesign
Grant awards (21)
Degrading therapeutically important kinases using small molecules$672,038
R01 · FY2025 · CA
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs$455,888
R01 · FY2025 · CA · contact PI
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase$403,964
R01 · FY2025 · CA · contact PI
Degrading therapeutically important kinases using small molecules$685,073
R01 · FY2024 · CA
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs$433,095
R01 · FY2024 · CA · contact PI
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase$378,504
R01 · FY2024 · CA · contact PI
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs$446,771
R01 · FY2023 · CA · contact PI
Degrading therapeutically important kinases using small molecules$389,510
R01 · FY2023 · CA
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase$388,760
R01 · FY2023 · CA · contact PI
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs$487,238
R01 · FY2022 · CA · contact PI
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase$406,564
R01 · FY2022 · CA · contact PI
Degrading therapeutically important kinases using small molecules$220,171
R01 · FY2022 · CA
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.$395,901
R01 · FY2021 · CA · contact PI
Degrading therapeutically important kinases using small molecules$365,491
R01 · FY2021 · CA
Degrading therapeutically important kinases using small molecules$284,744
R01 · FY2021 · CA
Degrading therapeutically important kinases using small molecules$650,235
R01 · FY2020 · CA
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.$395,901
R01 · FY2020 · CA · contact PI
Degrading therapeutically important kinases using small molecules$650,235
R01 · FY2019 · CA
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.$384,023
R01 · FY2019 · CA · contact PI
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.$410,426
R01 · FY2018 · CA · contact PI
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.$426,818
R01 · FY2017 · CA · contact PI